Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05567393 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-951 in Healthy Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT05567393 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 128 participants.
The verdict
NCT05567393, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
This is a study of TAK-951 for people with symptoms of nausea and vomiting. The main aims of this study in healthy adults are as follows: * To check for side effects from TAK-951 when given at a slow and fast infusion rate. * To learn how much TAK-951 participants can receive without getting side effects from it. * To check how much TAK-951 stays in the blood over time to work out the best dose. Participants will receive a single infusion of either TAK-951 or placebo. In this study, a placebo looks like TAK-951 but does not have any medicine in it. Participants will receive either a low dose or high dose of TAK-951. The infusion will take from 1-3 hours. Participants will stay in the study clinic for about 4 days to receive the study medicine (TAK-951 or placebo) and check for side effects. They will have follow-up visits at the clinic about 2 weeks and 4 weeks after treatment.
Interventions
- DRUG TAK-951
- DRUG TAK-951 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2019-03-07 |
| Est. Completion | 2020-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05567393
The ClinicalTrials.gov registry entry for NCT05567393 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-951 is the first listed.
NCT05567393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05567393 about?
NCT05567393 is a clinical study titled "A Study of TAK-951 in Healthy Adults". This is a study of TAK-951 for people with symptoms of nausea and vomiting. The main aims of this study in healthy adults are as follows: * To check for side effects from TAK-951 when given at a slow and fast infusion rate. * To learn how much TAK-951 participants can receive without getting side e...
What is the current status of trial NCT05567393?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2019-03-07. Estimated completion is 2020-11-02.
What interventions are being tested in trial NCT05567393?
The interventions under investigation include: TAK-951 (DRUG), TAK-951 Placebo (DRUG).
Who is sponsoring clinical trial NCT05567393?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.